FDA’s Trigger Policy For Generic Lawsuit Decisions “Facilitates Certainty,” Court Rules
This article was originally published in The Pink Sheet Daily
Executive Summary
The decision will uphold FDA’s newly created policy, barring a dissenting opinion from the District Court of Appeals.
You may also be interested in...
D.C. Circuit Court Stays Approval Of Pravachol ANDAs
The D.C. Circuit Court of Appeals enjoined FDA from granting final approval to any ANDA for generic versions of Bristol-Myers Squibb's cholesterol therapy Pravachol (pravastatin) April 20
D.C. Circuit Court Stays Approval Of Pravachol ANDAs
The D.C. Circuit Court of Appeals enjoined FDA from granting final approval to any ANDA for generic versions of Bristol-Myers Squibb's cholesterol therapy Pravachol (pravastatin) April 20
Teva’s Generic Pravachol Will Be Approved – With Exclusivity, FDA Decrees
FDA has determined that a court dismissal does not constitute a decision under the “court decision trigger” provision, although the agency’s stance must be affirmed by the D.C. district court.